A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma
- PMID: 3311924
- DOI: 10.1016/0090-8258(87)90210-1
A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma
Abstract
Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical